IA-05592

IA-05592: sourced facts only. name: "IA-05592, a novel orally bioavailable small-molecule PD-L1 inhibitor, was developed using structure-based drug design to disrupt PD-1/PD-L1 interactions." [DOI:10.1158/1538-7445.am2025-3213]; target: "IA-05592, a novel orally bioavailable small-molecule PD-L1 inhibitor, was developed using structure-based drug design to disrupt PD-1/PD-L1 interactions." [DOI:10.1158/1538-7445.am2025-3213]; developer: "1ILAb Co., Ltd., Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea;" [DOI:10.1158/1538-7445.am2025-3213]; modality: "IA-05592, a novel orally bioavailable small-molecule PD-L1 inhibitor, was developed using structure-based drug design to disrupt PD-1/PD-L1 interactions." [DOI:10.1158/1538-7445.am2025-3213]; stage: "In vivo, daily oral administration of IA-05592 in a human PD-L1 knock-in MC38 syngeneic mouse model at doses of 10, 30, and 90 mg/kg resulted in dose-dependent tumor reduction." [DOI:10.1158/1538-7445.am2025-3213]